Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) FCF Margin: 2019-2025

Historic FCF Margin for Revolution Medicines (RVMD) over the last 5 years, with Sep 2025 value amounting to 1,843.37%.

  • Revolution Medicines' FCF Margin was N/A to 1,843.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 7,271.94%, marking a year-over-year change of. This contributed to the annual value of 22,458.23% for FY2024, which is 2555236.00% up from last year.
  • Revolution Medicines' FCF Margin amounted to 1,843.37% in Q3 2025, which was up 137.12% from -4,966.61% recorded in Q4 2024.
  • In the past 5 years, Revolution Medicines' FCF Margin ranged from a high of 5,828.66% in Q1 2024 and a low of -16,560.65% during Q4 2023.
  • Its 3-year average for FCF Margin is -2,759.06%, with a median of -1,349.55% in 2023.
  • Its FCF Margin has fluctuated over the past 5 years, first plummeted by 1,613,883bps in 2023, then soared by 1,159,404bps in 2024.
  • Over the past 5 years, Revolution Medicines' FCF Margin (Quarterly) stood at -427.57% in 2021, then surged by 576bps to -421.81% in 2022, then tumbled by 1,613,883bps to -16,560.65% in 2023, then skyrocketed by 1,159,404bps to -4,966.61% in 2024, then reached 1,843.37% in 2025.
  • Its last three reported values are 1,843.37% in Q3 2025, -4,966.61% for Q4 2024, and 5,828.66% during Q1 2024.